EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

First‐In‐Human Safety, Pharmacokinetics, and Pharmacodynamics of VENT‐02 Freebase, a CNS‐Penetrant NLRP3 Inhibitor

Lisanne C A Smidt iD, Matthijs Moerland iD, Manon A A Jansen iD, Philip H C Kremer iD, Alexandra A J Sille iD, Pamela K Strugala iD, Erica S Klaassen iD, Anick Auger, Silvana Jananji, Rania Faidi iD, Kelly A Pike iD, Loraine Warner und 3 weitere

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70578 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Lisanne C A Smidt und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, the Netherlands. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The NLRP3 inflammasome is a central mediator of innate immunity and a key driver of inflammatory and neurodegenerative diseases. VENT‐02 is orally bioavailable, central nervous system‐penetrant, selective small‐molecule inhibitor of NLRP3. This first‐in‐human, randomized, double‐blind, placebo‐controlled study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of VENT‐02 freebase in healthy volunteers. The study consisted of single and multiple ascending dose phases, a food‐effect cohort, and a cerebrospinal fluid sampling cohort. VENT‐02 was safe and well tolerated at single doses up to 1600 mg and at multiple doses up to 200 mg twice daily (b.i.d.), with only mild treatment‐related adverse events at these dose levels. At 400 mg b.i.d., moderate treatment‐emergent adverse events occurred in 5 of 12 participants (41.7%). VENT‐02 was rapidly absorbed in plasma, with a median T max of 1.5–2.0 h in fasted state and had a terminal half‐life of 10–14 h at doses up to 500 mg. Exposure was dose‐proportional up to 500 mg, and a high‐fat, high‐calorie meal did not affect exposure significantly. VENT‐02 demonstrated central nervous system penetration, with a cerebrospinal fluid‐to‐plasma unbound concentration ratio of 0.43. VENT‐02 dose‐dependently inhibited release of IL‐1β and IL‐18 ex vivo in whole blood, with complete inhibition throughout the dosing interval at ≥ 200 mg b.i.d. VENT‐02 also dose‐dependently attenuated IL‐6 levels in plasma. In conclusion, 1 week of VENT‐02 b.i.d. dosing was found to be safe and tolerable at doses achieving complete systemic NLPR3‐inhibition. These findings support further clinical development of VENT‐02 in inflammatory and neurodegenerative diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinHumansMaleDouble-Blind MethodAdultFemaleMiddle AgedInflammasomesYoung AdultDose-Response Relationship, DrugHealthy VolunteersAdministration, OralInterleukin-1betaInterleukin-18

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanInflammasomesInterleukin-1betaInterleukin-18

Autor:innen und Institutionen

  • Centre for Human Drug Research, Leiden, the Netherlands.
  • Leiden University Medical Centre, Leiden, the Netherlands.
  • Ventus Therapeutics, Inc., Montreal, Quebec, Canada.
  • Ventus Therapeutics U.S., Inc., Waltham, Massachusetts, USA.

ORCID-Profile: Lisanne C A Smidt, Matthijs Moerland, Manon A A Jansen, Philip H C Kremer, Alexandra A J Sille, Pamela K Strugala, Erica S Klaassen, Rania Faidi, Kelly A Pike, Andre Matta, Ofer Spiegelstein

Zitieren

APA

Smidt, L. C. A., Moerland, M., Jansen, M. A. A., Kremer, P. H. C., Sille, A. A. J., Strugala, P. K., Klaassen, E. S., Auger, A., Jananji, S., Faidi, R., Pike, K. A., Warner, L., Matta, A., Valencia, X., & Spiegelstein, O. (2026). First‐In‐Human Safety, Pharmacokinetics, and Pharmacodynamics of VENT‐02 Freebase, a CNS‐Penetrant NLRP3 Inhibitor. Clinical and Translational Science. https://doi.org/10.1111/cts.70578

Vancouver

Smidt LCA, Moerland M, Jansen MAA, Kremer PHC, Sille AAJ, Strugala PK, et al. First‐In‐Human Safety, Pharmacokinetics, and Pharmacodynamics of VENT‐02 Freebase, a CNS‐Penetrant NLRP3 Inhibitor. Clinical and Translational Science. 2026. doi:10.1111/cts.70578

BibTeX
@article{Smidt2026,
  author = {Smidt, Lisanne C A and Moerland, Matthijs and Jansen, Manon A A and Kremer, Philip H C and Sille, Alexandra A J and Strugala, Pamela K and Klaassen, Erica S and Auger, Anick and Jananji, Silvana and Faidi, Rania and Pike, Kelly A and Warner, Loraine and Matta, Andre and Valencia, Xavier and Spiegelstein, Ofer},
  title = {First‐In‐Human Safety, Pharmacokinetics, and Pharmacodynamics of VENT‐02 Freebase, a CNS‐Penetrant NLRP3 Inhibitor},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70578}
}
Kostenlos starten →